Evidence map›Paper›PMID 42901931›Full record

ArticleNPJ digital medicine2026

MEDA-PKD: a dynamic, real-time analytics platform for precision care in autosomal dominant polycystic kidney disease.

Franziska Grundmann, Sita Arjune, Samer Alkarkoukly, Malte P Bartram, Bodo B Beck, Thomas Benzing, Volker Boehm, Katrin Bohl, Volker Burst, Martin Busch and 15 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02497521 (The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02497521 recruitingnot on this map

The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.

Typeobservational_patient_registrySponsorUniversity of CologneRan2015 to 2027Enrolled2,000ConditionsADPKD (Autosomal Dominant Polycystic Kidney Disease)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Franziska Grundmann *Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Sita Arjune *Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Samer AlkarkouklyDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Malte P BartramDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Bodo B BeckInstitute of Human Genetics, University of Cologne Faculty of Medicine and University Hospital Cologne, Würzburg, Germany.
Thomas BenzingDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Volker BoehmInstitute for Genetics, University of Cologne, Cologne, Germany.
Katrin BohlDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Volker BurstDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Martin BuschDepartment of Internal Medicine III, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany.
Figen CakirogluDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Sadrija CukoskiDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Peter GerkeNierenzentrum Lübeck, Lübeck, Germany.
Nils Große-HokampInstitute for Diagnostic and Interventional Radiology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Jan HalbritterDepartment of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Ludwig MatrischDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Thorsten PersigehlInstitute for Diagnostic and Interventional Radiology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Friederike PetzoldDivision of Nephrology, Department of Endocrinology, Nephrology, and Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
Johannes SchmidtCenter of Excellence in Nephrology, University Hospitals Aachen, Cologne, Düsseldorf, North Rhine-Westphalia, Germany.
Roland SchmittDepartment of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
Polina TodorovaCenter of Excellence in Nephrology, University Hospitals Aachen, Cologne, Düsseldorf, North Rhine-Westphalia, Germany.
Christoph WannerDepartment of Clinical Studies and Epidemiology, Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany.
Philipp AntczakDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. philipp.antczak@uk-koeln.de.
Roman-Ulrich MüllerDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. roman-ulrich.mueller@med.uni-duesseldorf.de.
AD(H)PKD Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of medical real-world data is constrained by fragmented data infrastructures and the absence of tools integrating longitudinal clinical with molecular data at scale. Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic cause of kidney failure, exemplifies this gap given its phenotypic complexity and the need for individualized treatment decisions. We present MEDA-PKD (MEdical DAta translation service of Polycystic Kidney Disease), an interactive, near-real-time analytics platform that integrates clinical routine with research data from the German AD(H)PKD Tolvaptan Registry (NCT02497521, DRKS00008910) into a harmonized database ( https://doi.org/10.18716/adpkd_registry ). MEDA-PKD provides automated near-real-time analysis and dynamic visualization, replacing traditional static approaches to clinical cohorts. As of March 2026, MEDA-PKD visualized data from 1735 patients (mean follow-up 796 days). eGFR slope analysis of data from patients initiating tolvaptan therapy (332 patients) demonstrates the platform's capacity to evaluate real-world therapeutic impact in real-time. Other tabs include family history, medication, lifestyle, quality of life and a wide array of lab values (20,894 entries). Besides, MEDA-PKD integrates proteomics data and allows for secure individual patient-level data access. MEDA-PKD represents a paradigm shift by transforming static cohort data into a living, actionable knowledge resource in ADPKD and will serve as a template for other diseases.

Identifiers

PMID42901931
PMCPMC13683356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.